Angiopoietin-2 signaling in retinal and choroidal vascular diseases: mechanisms, clinical evidence, and therapeutic implications
Currently, intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs remains the first-line therapy for most pathological retinal and choroidal vascular diseases. However, the suboptimal efficacy of conventional anti-VEGF drugs and the burden of repeated injections compromise treatment outcomes i...